The authors believe that the disconnect between protein biomarker discovery and routine test application can,to a certain extent, be solved by robust, multiplexed,and standardized alternative technologies. In our opinion,MS-based qCCP has the potential to replace or at least supplement quantitative clinical immunoassays provided the MS-based methods are robust, immunoassay- independent,cost-effective, and standardizable. Moreover, when clinically acceptable turnaround times can be realized the MS-based qCCP assays can be powerful alternatives for current
immunoassays, especially because they will offer opportunities for multiplexed evaluation of candidate biomarker panels. Standardization of the qCCP methods implies that
the concepts of metrological traceability and commutability of calibrators can be applied successfully. In that case it is feasible to standardize test results to a gold standard RM and RMP, and/or to harmonize to a pre-defined RM